IRF7 activation by Epstein-Barr virus latent membrane protein 1 requires localization at activation sites and TRAF6, but not TRAF2 or TRAF3

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 47, 2008, Pages 18448-18453

  Song, Yoon Jae ^a   Izumi, Kenneth M ^b   Shinners, Nicholas P ^a   Gewurz, Benjamin E ^a   Kieff, Elliott ^a  

^a CHANNING LABORATORY   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Adaptive immune; Cancer; Innate immune; Interferon; Lymphoma

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 7; LATENT MEMBRANE PROTEIN 1; PROTEIN; RIP1 PROTEIN; TBK1 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 3; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SENDAI VIRUS;

HUMANS; IMMUNOPRECIPITATION; INTERFERON REGULATORY FACTOR-7; INTERFERONS; NF-KAPPA B; NUCLEAR PORE COMPLEX PROTEINS; PROTEIN BINDING; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED DEATH DOMAIN PROTEIN; TNF RECEPTOR-ASSOCIATED FACTOR 2; TNF RECEPTOR-ASSOCIATED FACTOR 3; TNF RECEPTOR-ASSOCIATED FACTOR 6; TWO-HYBRID SYSTEM TECHNIQUES; VIRAL MATRIX PROTEINS;

HUMAN HERPESVIRUS 4; SENDAI VIRUS;

EID: 57449104909     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0809933105     Document Type: Article

References (54)

1. Kieff ED, Rickinson AB (2007) Epstein-Barr virus and its replication. Fields Virology, eds Knipe DM, Howley PM (Lippincott, Williams, and Wilkins Philadelphia) pp 2603-2655.
2. Mitchell T, Sugden B (1995) Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 69:2968-2976.
3. Huen DS, Henderson SA, Croom-Carter D, Rowe M (1995) The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-kappa B and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549-560.
4. Devergne O, et al. (1998) Role of the TRAF binding site and NF-kappaB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 72:7900-7908.
5. Devergne O, et al. (1996) Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-kappaB activation. Mol Cell Biol 16:7098-7108.
6. Mosialos G, et al. (1995) The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389-399.
7. Kaye KM, et al. (1996) Tumor necrosis factor receptor associated factor 2 is amediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc Natl Acad Sci USA 93:11085-11090.
8. Kaye KM, Izumi KM, Mosialos G, Kieff E (1995) The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues. J Virol 69:675-683.
9. Izumi KM, et al. (1999) The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation. J Virol 73:9908-9916.
10. Izumi KM, et al. (1999) The Epstein-Barr virus oncoprotein latent membrane protein 1 engages the tumor necrosis factor receptor-associated proteins TRADD and receptorinteracting protein (RIP) but does not induce apoptosis or require RIP for NF-kappaB activation. Mol Cell Biol 19:5759-5767.
11. Izumi KM, Kaye KM, Kieff ED (1997) The Epstein-Barr virus LMP1 amino acid sequence that engages tumor necrosis factor receptor associated factors is critical for primary B lymphocyte growth transformation. Proc Natl Acad Sci USA 94:1447-1452.
12. Izumi KM, Kieff ED (1997) The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 94:12592-12597.
13. Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW, Young LS (1999) Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J Biol Chem 274:16085-16096.
14. Eliopoulos AG, Blake SM, Floettmann JE, Rowe M, Young LS (1999) Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol 73:1023-1035.
15. Eliopoulos AG, et al. (1997) Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptorassociated factors. Oncogene 14:2899-2916.
16. Eliopoulos AG, et al. (1996) CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: Involvement of TRAF3 as a common mediator. Oncogene 13:2243-2254.
17. Kieser A, et al. (1997) Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J 16:6478-6485.
18. Zhang L, Wu L, Hong K, Pagano JS (2001) Intracellular signaling molecules activated by Epstein-Barr virus for induction of interferon regulatory factor 7. J Virol 75:12393-12401.
19. Zhang L, Pagano JS (2001) Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1. J Virol 75:341-350.
20. Huye LE, Ning S, Kelliher M, Pagano JS (2007) Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Mol Cell Biol 27:2910-2918.
21. Sato M, et al. (2000) Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 13:539-548.
22. Honda K, et al. (2004) Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc Natl Acad Sci USA 101:15416-15421.
23. Honda K, et al. (2005) Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. Nature 434:1035-1040.
24. Honda K, et al. (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434:772-777.
25. Lin R, Mamane Y, Hiscott J (2000) Multiple regulatory domains control IRF-7 activity in response to virus infection. J Biol Chem 275:34320-34327.
26. Colina R, et al. (2008) Translational control of the innate immune response through IRF-7. Nature 452:323-328.
27. Uematsu S, et al. (2005) Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med 201:915-923.
28. Zhang L, Pagano JS (2000) Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1. J Virol 74:1061-1068.
29. Ozato K, Tailor P, Kubota T (2007) The interferon regulatory factor family in host defense: Mechanism of action. J Biol Chem 282:20065-20069.
30. Kawai T, et al. (2004) Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5:1061-1068.
31. Floettmann JE, Rowe M (1997) Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-kappaB activation. Oncogene 15:1851-1858.
32. Kieser A, Kaiser C, HammerschmidtW(1999) LMP1 signal transduction differs substantially from TNF receptor 1 signaling in the molecular functions of TRADD and TRAF2. EMBO J 18:2511-2521.
33. Ning S, Hahn AM, Huye LE, Pagano JS (2003) Interferon regulatory factor 7 regulates expression of Epstein-Barr virus latent membrane protein 1:Aregulatory circuit. J Virol 77:9359-9368.
34. Soni V, Yasui T, Cahir-McFarland E, Kieff E (2006) LMP1 transmembrane domain 1 and 2 (TM1-2) FWLY mediates intermolecular interactions with TM3-6 to activate NF-kappaB. J Virol 80:10787-10793.
35. Yasui T, Luftig M, Soni V, Kieff E (2004) Latent infection membrane protein transmembrane FWLY is critical for intermolecular interaction, raft localization, and signaling. Proc Natl Acad Sci USA 101:278-283.
36. Eliopoulos AG, Young LS (1998) Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1). Oncogene 16:1731-1742.
37. Michallet MC, et al. (2008) TRADD protein is an essential component of the RIG-like helicase antiviral pathway. Immunity 28:651-661.
38. Chau TL, et al. (2008) Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated? Trends Biochem Sci 33:171-180.
39. Sharma S, et al. (2003) Triggering the interferon antiviral response through an IKK-related pathway. Science 300:1148-1151.
40. Zhao T, et al. (2007) The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways. Nat Immunol 8:592-600.
41. Luftig M, et al. (2003) Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. Proc Natl Acad Sci USA 100:15595-15600.
42. Song YJ, Jen KY, Soni V, Kieff E, Cahir-McFarland E (2006) IL-1 receptor-associated kinase 1 is critical for latent membrane protein 1-induced p65/RelA serine 536 phosphorylation and NF-kappaB activation. Proc Natl Acad Sci USA 103:2689-2694.
43. Shaffer AL, et al. (2008) IRF4 addiction in multiple myeloma. Nature 454:226-231.
44. Webster-Cyriaque J, Middeldorp J, Raab-Traub N (2000) Hairy leukoplakia: An unusual combination of transforming and permissive Epstein-Barr virus infections. J Virol 74:7610-7618.
45. Yuan J, Cahir-McFarland E, Zhao B, Kieff E (2006) Virus and cell RNAs expressed during Epstein-Barr virus replication. J Virol 80:2548-2565.
46. Cahir-McFarland ED, et al. (2004) Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 78:4108-4119.
47. Panne D, Maniatis T, Harrison SC (2004) Crystal structure of ATF-2/c-Jun and IRF-3 bound to the interferon-beta enhancer. EMBO J 23:4384-4393.
48. Wathelet MG, et al. (1998) Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol Cell 1:507-518.
49. Garner JG, Hirsch MS, Schooley RT (1984) Prevention of Epstein-Barr virus-induced B-cell outgrowth by interferon alpha. Infect Immun 43:920-924.
50. Swaminathan S, Hesselton R, Sullivan J, Kieff E (1993) Epstein-Barr virus recombinants with specifically mutated BCRF1 genes. J Virol 67:7406-7413.
51. Rickinson AB, Kieff ED (2007) Epstein-Barr Virus. Fields Virology, eds Knipe DM, Howley PM (Lippincott, Williams, and Wilkins, Philadelphia, Pa) pp 2655-2700.
52. Fogg MH, Garry D, Awad A, Wang F, Kaur A (2006) The BZLF1 homolog of an Epstein-Barr-related gamma-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques. J Immunol 176:3391-3401.
53. Fogg MH, Kaur A, Cho YG, Wang F (2005) The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue. J Virol 79:12681-12691.
54. Portal D, Rosendorff A, Kieff E (2006) Epstein-Barr nuclear antigen leader protein coactivates transcription through interaction with histone deacetylase 4. Proc Natl Acad Sci USA 103:19278-19283.